164 related articles for article (PubMed ID: 7062419)
1. Cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy versus chloroethyl-cyclohexy-nitrosourea in the treatment of metastatic prostatic cancer.
Herr HW
J Urol; 1982 Mar; 127(3):462-5. PubMed ID: 7062419
[TBL] [Abstract][Full Text] [Related]
2. A comparison of hydroxyurea, methyl-chloroethyl-cyclohexy-nitrosourea and cyclophosphamide in patients with advanced carcinoma of the prostate.
Loening SA; Scott WW; deKernion J; Gibbons RP; Johnson DE; Pontes JE; Prout GR; Schmidt JD; Soloway MS; Chu TM; Gaeta JF; Slack NH; Murphy GP
J Urol; 1981 Jun; 125(6):812-6. PubMed ID: 7017170
[TBL] [Abstract][Full Text] [Related]
3. Cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil in advanced prostatic cancer: a randomized trial.
Muss HB; Howard V; Richards F; White DR; Jackson DV; Cooper MR; Stuart JJ; Resnick MI; Brodkin R; Spurr CL
Cancer; 1981 Apr; 47(8):1949-53. PubMed ID: 7194733
[TBL] [Abstract][Full Text] [Related]
4. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
[TBL] [Abstract][Full Text] [Related]
5. Cyclophosphamide, doxorubicin hydrochloride and 5-fluorouracil in advanced carcinoma of the prostate.
Soloway MS; Shippel RM; Ikard M
J Urol; 1979 Nov; 122(5):637-9. PubMed ID: 501816
[TBL] [Abstract][Full Text] [Related]
6. Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide. National Prostatic Cancer Project randomized trial.
Murphy GP; Priore RL; Scardino PT
Urology; 1988 Jul; 32(1):33-40. PubMed ID: 3291371
[TBL] [Abstract][Full Text] [Related]
7. Therapy of advanced colorectal carcinoma with 5-fluorouracil and cyclophosphamide in combination with either CCNU or methotrexate.
White DR; Richards F; Muss HB; Cooper MR; Spurr CL
Cancer; 1980 Feb; 45(4):662-5. PubMed ID: 6986968
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy of hormonally unresponsive prostatic carcinoma.
deKernion JB; Lindner A
Urol Clin North Am; 1984 May; 11(2):319-26. PubMed ID: 6233779
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. A prospective randomized study.
Cocconi G; De Lisi V; Boni C; Mori P; Malacarne P; Amadori D; Giovanelli E
Cancer; 1983 Feb; 51(4):581-8. PubMed ID: 6336981
[TBL] [Abstract][Full Text] [Related]
10. Advanced ovarian carcinoma: a prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF).
Carmo-Pereira J; Costa FO; Henriques E; Ricardo JA
Cancer; 1981 Nov; 48(9):1947-51. PubMed ID: 6271386
[TBL] [Abstract][Full Text] [Related]
11. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.
Bennett JM; Muss HB; Doroshow JH; Wolff S; Krementz ET; Cartwright K; Dukart G; Reisman A; Schoch I
J Clin Oncol; 1988 Oct; 6(10):1611-20. PubMed ID: 3049953
[TBL] [Abstract][Full Text] [Related]
12. Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.
Kaltsas GA; Mukherjee JJ; Isidori A; Kola B; Plowman PN; Monson JP; Grossman AB; Besser GM
Clin Endocrinol (Oxf); 2002 Aug; 57(2):169-83. PubMed ID: 12153595
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study.
Mariani G; Petrelli F; Zambetti M; Moliterni A; Fasolo A; Marchiano A; Valagussa P; Gianni L
Clin Breast Cancer; 2006 Oct; 7(4):321-5. PubMed ID: 17092399
[TBL] [Abstract][Full Text] [Related]
14. Low dose chemotherapy of metastatic breast cancer with cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil (CAMF) versus sequential cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and adriamycin.
Creech RH; Catalano RB; Harris DT; Engstrom PF; Grotzinger PJ
Cancer; 1979 Jan; 43(1):51-9. PubMed ID: 367574
[TBL] [Abstract][Full Text] [Related]
15. Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer: a randomized trial.
Chlebowski RT; Hestorff R; Sardoff L; Weiner J; Bateman JR
Cancer; 1978 Dec; 42(6):2546-52. PubMed ID: 365313
[TBL] [Abstract][Full Text] [Related]
16. A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma.
Smalley RV; Bartolucci AA; Hemstreet G; Hester M
J Urol; 1981 Feb; 125(2):191-5. PubMed ID: 7206052
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma.
Page JP; Levi JA; Woods RL; Tattersall MN; Fox RM; Coates AS
Cancer Treat Rep; 1985 Jan; 69(1):105-7. PubMed ID: 3881176
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy of advanced breast cancer: a randomized trial of vincristine, Adriamycin, and cyclophosphamide (VAC) versus cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP).
Carmo-Pereira J; Costa FO; Henriques E
Cancer; 1981 Oct; 48(7):1517-21. PubMed ID: 7026020
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy of advanced small-cell anaplastic carcinoma. Superiority of a four-drug combination to a three-drug combination.
Hansen HH; Dombernowsky P; Hansen M; Hirsch F
Ann Intern Med; 1978 Aug; 89(2):177-81. PubMed ID: 209710
[TBL] [Abstract][Full Text] [Related]
20. Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A Southwest Oncology Group study.
Wozniak AJ; Blumenstein BA; Crawford ED; Boileau M; Rivkin SE; Fletcher WS
Cancer; 1993 Jun; 71(12):3975-8. PubMed ID: 8508363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
